CRDF
Price
$0.88
Change
+$0.08 (+10.00%)
Updated
Oct 27 closing price
Capitalization
68.08M
8 days until earnings call
Intraday BUY SELL Signals
INM
Price
$1.59
Change
-$0.00 (-0.00%)
Updated
Oct 27 closing price
Capitalization
8.74M
8 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRDF vs INM

CRDF vs INM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRDF vs. INM commentary
Oct 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Buy and INM is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRDF with price predictions
Oct 27, 2026

CRDF's Stochastic Oscillator stays in oversold zone for 21 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRDF's RSI Indicator exited the oversold zone, 20 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

Following a +6.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDF as a result. In 81 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for CRDF turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 30 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

CRDF moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for CRDF entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.566) is normal, around the industry mean (2.974). P/E Ratio (-1.459) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for INM with price predictions
Oct 27, 2026

Momentum Indicator for INM turns positive, indicating new upward trend

INM saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 81 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

INM moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for INM crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +19.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where INM advanced for three days, in 152 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

INM broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INM entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. INM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.126) is normal, around the industry mean (8.432). P/E Ratio (-0.510) is within average values for comparable stocks, (-1.821). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.891) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRDF vs INM: Fundamental Ratings
CRDF
INM
OUTLOOK RATING
1..100
5910
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
8637
P/E GROWTH RATING
1..100
4646
SEASONALITY SCORE
1..100
5044

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (51) in the null industry is in the same range as CRDF (68). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

INM's Profit vs Risk Rating (100) in the null industry is in the same range as CRDF (100). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

CRDF's SMR Rating (98) in the null industry is in the same range as INM (99). This means that CRDF’s stock grew similarly to INM’s over the last 12 months.

INM's Price Growth Rating (37) in the null industry is somewhat better than the same rating for CRDF (86). This means that INM’s stock grew somewhat faster than CRDF’s over the last 12 months.

INM's P/E Growth Rating (46) in the null industry is in the same range as CRDF (46). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFINM
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 14 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 28, 2026
Stock price -- (CRDF: $0.88 vs. INM: $1.59)
Brand notoriety: CRDF and INM are both not notable
CRDF represents the Biotechnology, while INM is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRDF: 93% vs. INM: 226%
Market capitalization -- CRDF: $68.08M vs. INM: $8.74M
CRDF [@Biotechnology] is valued at $68.08M. INM’s [@Pharmaceuticals: Generic] market capitalization is $8.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.06B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.14B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green while INM’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • INM’s FA Score: 0 green, 5 red.
According to our system of comparison, INM is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 4 TA indicator(s) are bullish while INM’s TA Score has 4 bullish TA indicator(s).

  • CRDF’s TA Score: 4 bullish, 6 bearish.
  • INM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INM is a better buy in the short-term than CRDF.

Price Growth

CRDF (@Biotechnology) experienced а -6.05% price change this week, while INM (@Pharmaceuticals: Generic) price change was +18.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.92%. For the same industry, the average monthly price growth was -10.60%, and the average quarterly price growth was +6.14%.

Reported Earning Dates

CRDF is expected to report earnings on Nov 05, 2026.

INM is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-2.92% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
CRDF
Daily Signal:
Gain/Loss:
INM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CRDF and

Correlation & Price change

A.I.dvisor tells us that CRDF and AXON have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRDF and AXON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
+8.80%
AXON - CRDF
33%
Poorly correlated
+0.26%
CLDX - CRDF
32%
Poorly correlated
+2.20%
DBVT - CRDF
32%
Poorly correlated
+1.45%
SNTI - CRDF
32%
Poorly correlated
+6.62%
AMLX - CRDF
31%
Poorly correlated
+4.47%
More

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with HYPD. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then HYPD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
N/A
HYPD - INM
39%
Loosely correlated
+4.91%
OMER - INM
36%
Loosely correlated
+7.37%
PULM - INM
30%
Poorly correlated
+3.47%
IXHL - INM
28%
Poorly correlated
+0.38%
CRDF - INM
28%
Poorly correlated
+8.80%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TARA2.470.12
+5.11%
Protara Therapeutics
CGBD10.490.23
+2.24%
Carlyle Secured Lending
BTLN3.240.05
+1.57%
Brightline Interactive Inc
AER150.052.17
+1.47%
Aercap Holdings NV
HNI47.63-0.07
-0.15%
HNI Corp